ПРЕДИАБЕТ ВА ИЛК АНИҚЛАНГАН 2-ТУР ҚАНДЛИ ДИАБЕТДА ТУРМУШ ТАРЗИНИ ЎЗГАРТИРИШ ВА МЕТФОРМИН ТЕРАПИЯСИНИНГ HOMA-IR КЎРСАТКИЧЛАРИГА ТАЪСИРИ
Keywords:
предиабет, 2-тур қандли диабет, инсулинрезистентлик, HOMA-IR, метформин, турмуш тарзини ўзгартириш, тана вазнини камайтириш.Abstract
Адабиётлар таҳлили асосида предиабет ва илк аниқланган 2-тур қандли диабетда (ҚД) турмуш тарзини ўзгартириш ва метформин терапиясининг инсулинрезистентлик кўрсаткичи HOMA-IR га таъсири ўрганилди. Интенсив турмуш тарзи ўзгартириши 2-тур ҚД ривожланиш хавфини 58%, метформин эса 31% га камайтириши, инсулинга сезувчанликни кўпроқ турмуш тарзи ўзгартириши яхшилаши, метформиннинг турмуш тарзи чораларига қўшилиши эса қўшимча самара бериши кўрсатилган. HOMA-IR инсулинрезистентликни баҳолаш ва даволаш самарадорлигини назорат қилишда оддий ва қулай усул ҳисобланади, бироқ унинг чекловларини ҳисобга олиш зарур.
References
1. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. – Brussels: International Diabetes Federation, 2021. – URL: https://diabetesatlas.org
2. American Diabetes Association Professional Practice Committee for Diabetes. 3. Prevention or delay of diabetes and associated comorbidities: Standards of Care in Diabetes—2026 // Diabetes Care. – 2026. – Vol. 49, Suppl. 1. – P. S50–S60. DOI: 10.2337/dc26-S003
3. Matthews D.R., Hosker J.P., Rudenski A.S. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man // Diabetologia. – 1985. – Vol. 28, № 7. – P. 412–419.
4. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling // Diabetes Care. – 2004. – Vol. 27, № 6. – P. 1487–1495.
5. Knowler W.C., Barrett-Connor E., Fowler S.E. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin // N Engl J Med. – 2002. – Vol. 346, № 6. – P. 393–403.
6. Tuomilehto J., Lindström J., Eriksson J.G. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance // N Engl J Med. – 2001. – Vol. 344, № 18. – P. 1343–1350.
7. Diabetes Prevention Program Research Group (Kitabchi A.E. et al.). Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program: effects of lifestyle intervention and metformin // Diabetes. – 2005. – Vol. 54, № 8. – P. 2404–2414.
8. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study // Lancet Diabetes Endocrinol. – 2015. – Vol. 3, № 11. – P. 866–875.
9. Amer B.E., Abdelgalil M.S., Hamad A.A. et al. Metformin plus lifestyle interventions versus lifestyle interventions alone for the delay or prevention of type 2 diabetes in individuals with prediabetes: a meta-analysis of randomized controlled trials // Diabetol Metab Syndr. – 2024. – Vol. 16. DOI: 10.1186/s13098-024-01504-8
10. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) // Lancet. – 1998. – Vol. 352, № 9131. – P. 854–865.
11. Lean M.E.J., Leslie W.S., Barnes A.C. et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial // Lancet. – 2018. – Vol. 391, № 10120. – P. 541–551.
12. Foretz M., Guigas B., Viollet B. Metformin: update on mechanisms of action and repurposing potential // Nat Rev Endocrinol. – 2023. – Vol. 19, № 8. – P. 460–476.
13. DeFronzo R.A. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus // Diabetes. – 2009. – Vol. 58, № 4. – P. 773–795.
Downloads
Published
Versions
- 2026-09-29 (2)
- 2026-09-29 (1)